Ultragenyx Pharmaceutical Inc.
For the period ended May 15, 2025. Filed Mar 28, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
May 15, 2025 · Filed Mar 28, 2025
Contents
Proxy Statement Overview
This overview highlights certain information contained elsewhere in this Proxy Statement and does not contain all of the information that you should consider. You should read the entire Proxy Statement carefully before voting. For more complete information regarding our business and 2024 performance, please review our 2024 Annual Report on Form 10-K as filed with the U.S. Securities and Exchange Commission (SEC) in February 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.